Vivos Therapeutics has received US Patent No. 12,697,190, enhancing its intellectual property protections. This broadens the coverage of its oral medical devices for obstructive sleep apnea, positioning the company favorably amid a growing market for effective treatments.
Key Highlights
- Shares are down 87.6% year-to-date, pushing market cap to approximately $6 million.
- Vivos’ devices received unprecedented FDA clearances to treat severe obstructive sleep apnea in adults and children.
- Vivos Therapeutics, Inc. (NASDAQ: VVOS) has bolstered its intellectual property portfolio with the issuance of US Patent No. 12,697,190.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) has bolstered its intellectual property portfolio with the issuance of US Patent No. 12,697,190.
Enhanced Patent Protections
These patents fortify the company's position against competitors by providing broader, layered protections that are difficult to circumvent. The new ‘190 Patent complements the existing patented technology by offering both detailed coverage for specific designs and broader claims.
Implications for Market Position
The environment for OSA treatments is shifting dramatically, with over 90 million Americans affected and many remaining undiagnosed. Given the documented health risks associated with CPAP devices, particularly the increase in mortality, Vivos’ innovative oral devices are positioned to address an urgent need for patients seeking safer alternatives. This patent may enhance investor confidence as the company aims to capture increasing market Demand for effective non-invasive treatments.
Industry Context and Future Outlook
The patent’s issuance is expected to strengthen Vivos' market leverage, particularly in a sector eager for viable therapeutic interventions. As Vivos navigates this environment, the clinical and commercial prospects for its devices appear increasingly promising, reinforced by the advanced technological framework justified by their patent protections.
Investors will be keenly watching Vivos' next Quarterly Report for financial updates and to assess any shifts in market strategy following this patent issuance.






Please wait processing your request...